NCT05461430Completed
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 72 (actual)
- First submitted
- 13 Jul 2022
- Start date
- 15 Jul 2022
- Primary completion date
- 23 Mar 2026
- Lead sponsor
- Travera Inc
- Diseases
- Melanoma, Bladder cancer, Kidney cancer, Head and neck cancer, Cervical cancer, Mesothelioma, Neuroendocrine tumours, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Ovarian cancer
- NCT number
- NCT05461430
What you commit to
- Study type: Observational
- Participants enrolled: 72
- From 15 Jul 2022 to the primary completion date, 23 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lack of informed consent
- Unable to obtain sufficient sample
Who the study is looking for
- Patient is ≥18 years of age
- Written Informed Consent provided by patient
- Diagnosis of any kind of carcinoma
- Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
- Proceeding onto therapy for treatment
- Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| xCures Coordinator of this site? Confirm its status | Oakland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.